Breast Cancer DetectionDMT SV RRS2NCT03972605
Delphinus SoftVue™ ROC Reader Study
An observational study of Breast Cancer Detection and Dense Breast Parenchyma, run by Delphinus Medical Technologies, Inc. at 1 site in United States.
Trial summary
The purpose of this multi-reader, multi-case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in women with dense breast parenchyma. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings
- What is being tested?
- Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
- Type of treatment
- Medical device
- How many people
- 32 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Jun 2019to 2 Jul 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Readers will evaluate mammography and SoftVue images acquired at study entry from consented participants in protocol DMT-2015.001, and subsequently categorized into the following case types, in random order: * Cancer cases, confirmed by breast biopsy with at least one lesion determined to be malignant during participation * Non-Cancer cases including, but not limited to benign cases, confirmed by breast biopsy with no lesions determined to be malignant, or normal/negative screening or diagnostic imaging during participation
Radiologists of any age, sex, race, ethnicity, or institutional affiliation may participate as study readers. All readers must meet the following base Inclusion Criteria:
- Hold a current United States medical license
- Be American Board of Radiology Certified
- Be MQSA-qualified
- Be experienced in reading DM images on a monitor
- Be experienced in reading Breast Ultrasound images on a monitor
- Have completed a Financial Disclosure showing no Conflicts of Interest
- Have provided a current curriculum vitae (CV)
- Have provided a signed Readers' Agreement
- Have provided written Informed Consent
All qualified and confirmed readers will complete a multi-module SoftVue™ training program prior to their participation in a reading session for this study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Retrospective, Observational, Case-controlled, Multi-reader, Multi-case, Receiver Operating Characteristic (ROC) Study of Reader Performance When SoftVue Automated Breast Ultrasound (SV) and Digital Screening Mammography (DM) Are Combined, Compared to Screening Mammography Alone, in Asymptomatic Women With Heterogeneous or Extremely Dense Breast Parenchyma.
The purpose of this multi-reader, multi-case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in women with dense breast parenchyma.
This reader study will include approximately 32 radiologist readers and a sample of approximately 200 breast screening cases to be selected from the library of images collected under Delphinus Protocol #DMT-2015.001 (NCT03257839) Arm 1 Phases B, C, and D. The reader study image case set will be enriched with cancer cases.
- Conditions
- Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
- Being tested
- Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
- Keywords
- Breast Screening, Breast Imaging, SoftVue, Mammography, Ultrasound, Reader Study, ROC AUC, Dense Breasts, Breast Density, Dense Breast Tissue, Breast Neoplasms
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Reading of Automated Breast Ultrasound in conjunction with Screening MammographyDevice
Also called Digital Screening Mammography with Adjunctive SoftVue Screening Whole Breast Ultrasound
Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
What is being measured
The primary outcome is the main question the study is designed to answer.
MRMC Analysis: ROC AUC
Area under the ROC curve (AUC)
Measured: 8 Weeks
Secondary outcomes (1)
Sensitivity and Specificity
True Positive Rate and True Negative Rate
Measured: 8 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2019
- Study start8 Jun 2019
- Primary completion2 Jul 2019
- Study completion2 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast Cancer DetectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Delphinus Medical Technologies, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Chicago, Boston Biomedical Associates, Reed Technical Associates, LLC
- Responsible party
- Sponsor
- Investigators
- Yulei Jiang, Ph.D, Principal investigator, University of ChicagoMary Ellen Giger, Ph.D, Principal investigator, Univeristy of Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03972605
- Sponsor's protocol ID
- DMT-2019.001
- Acronym
- DMT SV RRS2
- Status last verified
- Jan 2020
- First submitted
- 31 May 2019
- Last updated
- 28 Jan 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Retrospective, Observational, Case-controlled, Multi-reader, Multi-case, Receiver Operating Characteristic (ROC) Study of Reader Performance When SoftVue Automated Breast Ultrasound (SV) and Digital Screening Mammography (DM) Are Combined, Compared to Screening Mammography Alone, in Asymptomatic Women With Heterogeneous or Extremely Dense Breast Parenchyma.
- ClinicalTrials.gov ID
- NCT03972605
- Acronym / sponsor ID
- DMT SV RRS2 / DMT-2019.001
- Conditions
- Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
- Keywords
- Breast Screening, Breast Imaging, SoftVue, Mammography, Ultrasound, Reader Study, ROC AUC, Dense Breasts
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Delphinus Medical Technologies, Inc.Industry (pharma, biotech, devices)
- Collaborators
- University of Chicago, Boston Biomedical Associates, Reed Technical Associates, LLC
- Study start
- 8 Jun 2019 (actual)
- Primary completion
- 2 Jul 2019 (actual)
- Study completion
- 2 Jul 2019 (actual)
- First posted
- 3 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this multi-reader, multi-case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in women with dense breast parenchyma.
This reader study will include approximately 32 radiologist readers and a sample of approximately 200 breast screening cases to be selected from the library of images collected under Delphinus Protocol #DMT-2015.001 (NCT03257839) Arm 1 Phases B, C, and D. The reader study image case set will be enriched with cancer cases.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Readers will evaluate mammography and SoftVue images acquired at study entry from consented participants in protocol DMT-2015.001, and subsequently categorized into the following case types, in random order: * Cancer cases, confirmed by breast biopsy with at least one lesion determined to be malignant during participation * Non-Cancer cases including, but not limited to benign cases, confirmed by breast biopsy with no lesions determined to be malignant, or normal/negative screening or diagnostic imaging during participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Reading of Automated Breast Ultrasound in conjunction with Screening MammographyAlso: Digital Screening Mammography with Adjunctive SoftVue Screening Whole Breast UltrasoundReader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone. | Device | – |
Primary outcome
MRMC Analysis: ROC AUC
Time frame: 8 Weeks
Area under the ROC curve (AUC)
1 secondary outcome
Sensitivity and Specificity
Time frame: 8 Weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2020.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer Detection
RecruitingObservational study
Post-market Safety Study of LUMISIGHT
Hypersensitivity Reactions
RecruitingObservational study
Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry
Breast Cancer
Active, not recruitingObservational study
Breast MRI for Early Detection of Breast Cancer in Thuringia
Breast Cancer
Not yet recruiting
Increasing Breast and Colorectal Cancer Screening in the Community
Colorectal Neoplasms, Breast Neoplasms
Not yet recruiting
Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
Ovarian Neoplasms, BRCA 1 Gene Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yulei Jiang, Ph.D principal investigator
University of Chicago
Mary Ellen Giger, Ph.D principal investigator
Univeristy of Chicago
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer Detection and Dense Breast Parenchyma, run by Delphinus Medical Technologies, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MRMC Analysis: ROC AUC (time frame: 8 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2020.